Xencor Inc (XNCR)

$19.23

+0.21

(+1.1%)▲

Market is closed - opens 7 PM, 26 Apr 2024

Insights on Xencor Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 59.16M → 44.68M (in $), with an average decrease of 24.5% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -24.26M → -19.1M (in $), with an average increase of 27.1% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 52.5% return, outperforming this stock by 81.0%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 239.5% return, outperforming this stock by 296.3%

Performance

  • $18.32
    $19.74
    $19.23
    downward going graph

    4.73%

    Downside

    Day's Volatility :7.17%

    Upside

    2.56%

    downward going graph
  • $16.49
    $28.96
    $19.23
    downward going graph

    14.25%

    Downside

    52 Weeks Volatility :43.06%

    Upside

    33.6%

    downward going graph

Returns

PeriodXencor IncSector (Health Care)Index (Russel 2000)
3 Months
-4.23%
0.5%
0.0%
6 Months
9.32%
11.7%
0.0%
1 Year
-28.51%
6.2%
2.2%
3 Years
-56.84%
13.5%
-23.0%

Highlights

Market Capitalization
1.2B
Book Value
$10.96
Earnings Per Share (EPS)
-2.08
PEG Ratio
0.0
Wall Street Target Price
36.58
Profit Margin
-74.9%
Operating Margin TTM
-75.5%
Return On Assets TTM
-9.55%
Return On Equity TTM
-18.08%
Revenue TTM
168.3M
Revenue Per Share TTM
2.78
Quarterly Revenue Growth YOY
106.80000000000001%
Gross Profit TTM
-35.0M
EBITDA
-125.9M
Diluted Eps TTM
-2.08
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-3.33
EPS Estimate Next Year
-2.94
EPS Estimate Current Quarter
-0.09
EPS Estimate Next Quarter
-0.93

Analyst Recommendation

Buy
    90%Buy
    4%Hold
    4%Sell
Based on 21 Wall street analysts offering stock ratings for Xencor Inc(by analysts ranked 0 to 5 stars)
Based on 21 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
19
19
19
Hold
1
1
1
Sell
1
1
1

Analyst Forecast

What analysts predicted

Upside of 90.22%

Current $19.23
Target $36.58

Company Financials

FY18Y/Y Change
Revenue
40.6M
↑ 13.7%
Net Income
-70.4M
↑ 43.91%
Net Profit Margin
-173.41%
↓ 36.41%
FY19Y/Y Change
Revenue
156.7M
↑ 285.93%
Net Income
26.9M
↓ 138.17%
Net Profit Margin
17.15%
↑ 190.56%
FY20Y/Y Change
Revenue
122.7M
↓ 21.7%
Net Income
-63.5M
↓ 336.42%
Net Profit Margin
-51.79%
↓ 68.94%
FY21Y/Y Change
Revenue
275.1M
↑ 124.23%
Net Income
82.6M
↓ 230.05%
Net Profit Margin
30.04%
↑ 81.83%
FY22Y/Y Change
Revenue
164.6M
↓ 40.18%
Net Income
-55.2M
↓ 166.78%
Net Profit Margin
-33.53%
↓ 63.57%
FY23Y/Y Change
Revenue
168.3M
↑ 2.28%
Net Income
-126.1M
↑ 128.5%
Net Profit Margin
-74.9%
↓ 41.37%
Q3 FY22Q/Q Change
Revenue
27.3M
↓ 9.53%
Net Income
-32.8M
↓ 18.0%
Net Profit Margin
-120.0%
↑ 12.39%
Q4 FY22Q/Q Change
Revenue
21.6M
↓ 20.84%
Net Income
-12.0M
↓ 63.24%
Net Profit Margin
-55.72%
↑ 64.28%
Q1 FY23Q/Q Change
Revenue
19.0M
↓ 12.25%
Net Income
-59.9M
↑ 397.56%
Net Profit Margin
-315.98%
↓ 260.26%
Q2 FY23Q/Q Change
Revenue
45.5M
↑ 140.07%
Net Income
-22.0M
↓ 63.36%
Net Profit Margin
-48.23%
↑ 267.75%
Q3 FY23Q/Q Change
Revenue
59.2M
↑ 29.97%
Net Income
-24.3M
↑ 10.54%
Net Profit Margin
-41.02%
↑ 7.21%
Q4 FY23Q/Q Change
Revenue
44.7M
↓ 24.47%
Net Income
-19.1M
↓ 21.3%
Net Profit Margin
-42.74%
↓ 1.72%
FY18Y/Y Change
Total Assets
576.7M
↑ 47.84%
Total Liabilities
55.1M
↓ 49.05%
FY19Y/Y Change
Total Assets
670.3M
↑ 16.22%
Total Liabilities
77.0M
↑ 39.96%
FY20Y/Y Change
Total Assets
703.2M
↑ 4.92%
Total Liabilities
130.8M
↑ 69.76%
FY21Y/Y Change
Total Assets
838.2M
↑ 19.19%
Total Liabilities
104.7M
↓ 19.95%
FY22Y/Y Change
Total Assets
846.3M
↑ 0.96%
Total Liabilities
118.8M
↑ 13.43%
FY23Y/Y Change
Total Assets
952.7M
↑ 12.58%
Total Liabilities
283.6M
↑ 138.75%
Q3 FY22Q/Q Change
Total Assets
835.3M
↓ 1.89%
Total Liabilities
112.6M
↑ 3.29%
Q4 FY22Q/Q Change
Total Assets
846.3M
↑ 1.32%
Total Liabilities
118.8M
↑ 5.51%
Q1 FY23Q/Q Change
Total Assets
803.4M
↓ 5.06%
Total Liabilities
119.8M
↑ 0.89%
Q2 FY23Q/Q Change
Total Assets
778.1M
↓ 3.15%
Total Liabilities
99.2M
↓ 17.18%
Q3 FY23Q/Q Change
Total Assets
778.4M
↑ 0.04%
Total Liabilities
109.4M
↑ 10.25%
Q4 FY23Q/Q Change
Total Assets
952.7M
↑ 22.39%
Total Liabilities
283.6M
↑ 159.15%
FY18Y/Y Change
Operating Cash Flow
-79.8M
↑ 136.78%
Investing Cash Flow
-164.8M
↓ 615.7%
Financing Cash Flow
254.2M
↑ 6710.63%
FY19Y/Y Change
Operating Cash Flow
64.4M
↓ 180.71%
Investing Cash Flow
-51.0M
↓ 69.07%
Financing Cash Flow
10.7M
↓ 95.81%
FY20Y/Y Change
Operating Cash Flow
-5.0M
↓ 107.77%
Investing Cash Flow
100.2M
↓ 296.57%
Financing Cash Flow
18.0M
↑ 69.24%
FY21Y/Y Change
Operating Cash Flow
-16.9M
↑ 236.79%
Investing Cash Flow
-46.2M
↓ 146.16%
Financing Cash Flow
43.0M
↑ 138.52%
FY22Y/Y Change
Operating Cash Flow
24.5M
↓ 245.29%
Investing Cash Flow
-119.7M
↑ 158.87%
Financing Cash Flow
5.7M
↓ 86.75%
Q3 FY22Q/Q Change
Operating Cash Flow
-1.2M
↓ 102.64%
Investing Cash Flow
3.1M
↓ 104.13%
Financing Cash Flow
1.3M
↓ 48.79%
Q4 FY22Q/Q Change
Operating Cash Flow
-24.4M
↑ 1991.7%
Investing Cash Flow
24.5M
↑ 685.54%
Financing Cash Flow
1.2M
↓ 9.01%
Q1 FY23Q/Q Change
Operating Cash Flow
-30.6M
↑ 25.31%
Investing Cash Flow
48.1M
↑ 96.12%
Financing Cash Flow
922.0K
↓ 21.26%
Q2 FY23Q/Q Change
Operating Cash Flow
-38.2M
↑ 24.78%
Investing Cash Flow
-1.4M
↓ 102.92%
Financing Cash Flow
1.9M
↑ 108.35%

Technicals Summary

Sell

Neutral

Buy

Xencor Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Xencor Inc
Xencor Inc
-10.68%
9.32%
-28.51%
-56.84%
-39.05%
Moderna, Inc.
Moderna, Inc.
-1.15%
39.75%
-18.77%
-40.22%
304.34%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-7.56%
12.46%
14.48%
77.72%
159.17%
Novo Nordisk A/s
Novo Nordisk A/s
-2.8%
32.13%
52.48%
239.51%
414.16%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.96%
10.08%
23.01%
83.3%
130.08%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Xencor Inc
Xencor Inc
70.49
NA
0.0
-3.33
-0.18
-0.1
NA
10.96
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.04
26.04
1.46
45.0
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
47.43
47.43
2.4
3.35
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.81
28.81
0.53
16.75
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Xencor Inc
Xencor Inc
Buy
$1.2B
-39.05%
70.49
-74.9%
Moderna, Inc.
Moderna, Inc.
Buy
$41.7B
304.34%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$99.5B
159.17%
26.04
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$562.8B
414.16%
47.43
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$103.6B
130.08%
28.81
36.68%

Institutional Holdings

  • BlackRock Inc

    18.53%

  • PRIMECAP Management Company

    14.56%

  • Vanguard Group Inc

    11.07%

  • EcoR1 Capital, LLC

    8.64%

  • T. Rowe Price Associates, Inc.

    5.70%

  • State Street Corporation

    5.44%

Company Information

antibodies by design antibody and protein biotherapeutics are changing the way physicians treat autoimmune diseases, asthma, and cancer. at xencor, we apply proprietary protein engineering technologies to develop better biotherapeutics – antibodies that target new biological mechanisms and are more potent, safer and longer lasting – to improve patient outcomes and quality of life. our xmab antibody engineering technology dramatically augments natural antibody immune functions while maintaining over 99.5% identity to natural antibodies. this combination of new, highly potent activities while maintaining the beneficial drug features and simplicity of natural antibodies allows us to create differentiated drug candidates with potential for breakthrough performance. the xmab® platform has resulted in a robust pipeline of antibody product candidates, including eight in human clinical trials being developed by xencor and by pharmaceutical partners. xencor is also discovering biologics product

Organization
Xencor Inc
Employees
280
CEO
Dr. Bassil I. Dahiyat Ph.D.
Industry
Health Technology

Discover More

FAQs